VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
OMER
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
OMEROmeros Corporation
$16.68$1.2B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
OMER logo

Omeros Corporation

OMER
NASDAQ · Immunology Biotech
$16.68
At close - Nov 16, 4:00 PM EST - USD
Market Cap$1.21B
P/E12.0x
52W High$21.24
Volume1.43M
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q2

Commercial Launch Emerges Amidst Critical Liquidity and Solvency Risk

Omeros is at a pivotal inflection point, transitioning from a pure R&D entity to a commercial-stage biotech with the launch of YARTEMLEA, which generated $28.5 million in Q2 2026 revenue.

GrowthAccelerating
ProfitabilityStrained
ValuationAttractive
TechnicalsMixed
Explore valuation models
MARKET ACTION

OMER price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

10/12 Beats

EPS beat 10 of last 12 quarters

02

Valuation risk

-62% Peers

P/E is 62% below peer median

03

Market leadership

RS 94 · Leader

High momentum (Outperforming 94% of market)

04

Mixed Trend

Mixed

Price < 50DMA but > 200DMA

Next CatalystEstimated earnings · Feb 16

Market performance

Price History →

Trailing total returns as of 11/17/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
OMER+1.83%
S&P 500 (^GSPC)+8.31%
1-Year Return
OMER+83.70%
S&P 500 (^GSPC)+11.16%
3-Year Return
OMER+1004.64%
S&P 500 (^GSPC)+28.39%
5-Year Return
OMER+102.43%
S&P 500 (^GSPC)+50.91%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E5Y High
12.0x
Forward P/E
20.2x
EV/EBITDA
N/A
FCF YieldCash Flow
N/A

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
12.0x
4.9x
100th· High
EV/EBITDA
N/A
N/A
N/A
Price/FCF
N/A
2.8x
N/A
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
No DCF Model AvailableIntrinsic value modeling is not supported for this equity.

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
-
Net income FY25
-$3M+97.9% YoY
Free cash flow FY25
-$116M+22.0% YoY
Operating margin FY25
-
ROIC (FY25)-142.5%
Avg ROIC 5Y-69.5%
ROE (FY25)-
Piotroski Score3 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate10/12 (83%)
Revenue Beat Rate2/12 (67%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 16, 2026
$0.06+200.0%
vs $0.02
$36M-3.6%
vs $37M
Q3 2026
Aug 13, 2026
$0.15+155.9%
vs -$0.27
$29M+124.8%
vs $13M
Q2 2026
May 13, 2026
-$0.24+40.0%
vs -$0.40
$10M+136.4%
vs $4M
Q2 2026
Mar 31, 2026
$3.14+670.9%
vs -$0.55
—
vs $2M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
Business Wire·6d ago
Omeros Corporation to Announce Third Quarter Financial Results on November 16, 2026

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that it will issue its financial results for the third quarter of 2026 on Monday, November 16, 2026 after market close. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss recent developments and highlights as well as the Company's financial results. Conference Call Details and Webcast Link Instructions To access the live webcast, please c.

Defense World·Oct 18, 2026
Omeros (NASDAQ:OMER) Shares Gap Down – Here’s Why

Omeros Corporation (NASDAQ: OMER - Get Free Report)'s share price gapped down before the market opened on Friday. The stock had previously closed at $18.79, but opened at $17.94. Omeros shares last traded at $16.0010, with a volume of 695,394 shares traded. Key Omeros News Here are the key news stories impacting Omeros this week: Positive

Benzinga·Oct 16, 2026
Omeros Stock Sinks on Negative EU Opinion for Narsoplimab, Compassionate-Use Program Ends

Omeros Corporation (NASDAQ:OMER) shares are trading lower Friday after the company announced that the European Medicines Agency's CHMP issued a negative opinion on its marketing authorization application for narsoplimab in TA-TMA, following re-examination of its original negative opinion from June.

Business Wire·Oct 16, 2026
Omeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMA

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a negative opinion on the company's marketing authorization application (MAA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) following re-examination of its original negative opinion adopted in June 2026. An eight-member ad hoc expert group (.

Filtered for Omeros CorporationMore Headlines
04

Compare before deciding

Benchmark OMER against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Omeros Corporation (OMER)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
OMER logoOMEROmeros CorporationCurrent
$16.68$1.21B11.98—324.88%——
ACAD logoACADACADIA Pharmaceuticals Inc.
$18.67$3.2B9.0411.87%30.13%28.03%—
PTCT logoPTCTPTC Therapeutics, Inc.
$60.97$5.06B-48.03114.51%-9.17%——
RARE logoRAREUltragenyx Pharmaceutical Inc.
$15.90$1.57B-3.1020.13%-71.78%——
HALO logoHALOHalozyme Therapeutics, Inc.
$96.50$11.45B24.3737.55%26.93%544.26%—
PRTA logoPRTAProthena Corporation plc
$7.97$417.26M-17.16-92.84%-45.43%-8.34%—

Compare OMER vs Peers

Omeros Corporation (OMER) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs ACAD

Most directly comparable listed peer for OMER.

Scale Benchmark

vs IQV

Larger-name benchmark to compare OMER against a more recognizable public peer.

Peer Set

Compare Top 5

vs ACAD, PTCT, RARE, HALO

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

OMER SEC Filings & Documents

Omeros Corporation (OMER) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Aug 13, 2026·SEC

Material company update

Aug 12, 2026·SEC

Material company update

Jul 20, 2026·SEC

10-K Annual Reports

3
FY 2026

Mar 31, 2026·SEC

FY 2025

Mar 31, 2025·SEC

FY 2024

Apr 1, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Aug 12, 2026·SEC

FY 2026

May 13, 2026·SEC

FY 2025

Nov 13, 2025·SEC

Get notified when OMER posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

OMER Frequently Asked Questions

Omeros Corporation (OMER) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Omeros Corporation's revenue?

Omeros Corporation (OMER) reported $38.4M in revenue over the trailing twelve months.

Is OMER profitable?

Yes. Omeros Corporation (OMER) earned $124.8M in net income over the trailing twelve months (a 324.9% net margin).

Dividend & Returns
What is Omeros Corporation's free cash flow?

Omeros Corporation (OMER) had negative free cash flow of $68.7M over the trailing twelve months.

What if you invested $1,000 in OMER back in 2007?

Total return calculator · dividends reinvested · 19+ years of data

See returns →